DK0719331T4 - Eotaxin: Eosinophil chemotaktisk cytokin - Google Patents

Eotaxin: Eosinophil chemotaktisk cytokin

Info

Publication number
DK0719331T4
DK0719331T4 DK94926324.8T DK94926324T DK0719331T4 DK 0719331 T4 DK0719331 T4 DK 0719331T4 DK 94926324 T DK94926324 T DK 94926324T DK 0719331 T4 DK0719331 T4 DK 0719331T4
Authority
DK
Denmark
Prior art keywords
eotaxin
chemotactic cytokine
eosinophil chemotactic
eosinophil
cytokine
Prior art date
Application number
DK94926324.8T
Other languages
English (en)
Other versions
DK0719331T3 (da
Inventor
Peter John National Heart & Lung Institute Jose
Timothy John Williams
David A Griffiths-Johnson
John Justin Hsuan
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26303515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0719331(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB939318984A external-priority patent/GB9318984D0/en
Priority claimed from GB9408602A external-priority patent/GB9408602D0/en
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Application granted granted Critical
Publication of DK0719331T3 publication Critical patent/DK0719331T3/da
Publication of DK0719331T4 publication Critical patent/DK0719331T4/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
DK94926324.8T 1993-09-14 1994-09-14 Eotaxin: Eosinophil chemotaktisk cytokin DK0719331T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939318984A GB9318984D0 (en) 1993-09-14 1993-09-14 Chemotactic cytokine
GB9408602A GB9408602D0 (en) 1994-04-29 1994-04-29 Chemotactic cytokine
PCT/GB1994/002006 WO1995007985A1 (en) 1993-09-14 1994-09-14 Eotaxin: eosinophil chemotactic cytokine

Publications (2)

Publication Number Publication Date
DK0719331T3 DK0719331T3 (da) 2006-12-04
DK0719331T4 true DK0719331T4 (da) 2014-06-10

Family

ID=26303515

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94926324.8T DK0719331T4 (da) 1993-09-14 1994-09-14 Eotaxin: Eosinophil chemotaktisk cytokin

Country Status (12)

Country Link
US (6) US5993814A (da)
EP (1) EP0719331B2 (da)
JP (1) JPH09507211A (da)
AT (1) ATE344324T1 (da)
AU (1) AU687872B2 (da)
CA (1) CA2171761C (da)
DE (1) DE69434878T3 (da)
DK (1) DK0719331T4 (da)
ES (1) ES2274514T5 (da)
NZ (1) NZ273052A (da)
PT (1) PT719331E (da)
WO (1) WO1995007985A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507211A (ja) * 1993-09-14 1997-07-22 ナショナル ハート アンド ラング インスティチュート エオタキシン：好酸球走化性サイトカイン
US6100389A (en) 1995-04-21 2000-08-08 Human Genome Sciences, Inc. Polynucleotides encoding a human chemotactic protein
US6075124A (en) * 1994-05-16 2000-06-13 Human Genome Sciences, Inc. Human chemotactin protein
US7005509B1 (en) * 1995-02-17 2006-02-28 Incyte Corporation Chemokine PANEC-1 polynucleotides and compositions and methods related thereto
US6403782B1 (en) 1995-06-22 2002-06-11 President And Fellows Of Harvard College Nucleic acid encoding eotaxin
US7265201B1 (en) * 1995-06-23 2007-09-04 Millennium Pharmaceuticals, Inc. Human chemotactic cytokine
US6673915B1 (en) 1996-09-30 2004-01-06 General Hospital Corporation Nucleic acid encoding monocyte chemotactic protein 4
US6028169A (en) * 1997-03-31 2000-02-22 Human Genome Sciences, Inc. Chemokine β-6 antagonists
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
AU4230900A (en) 1999-04-08 2000-10-23 General Hospital Corporation, The Purposeful movement of human migratory cells away from an agent source
EP1259615B1 (en) 2000-03-03 2008-11-12 Cambridge Antibody Technology Limited Antibodies against eotaxin and their use
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
CA2420944A1 (en) 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
WO2002062296A2 (en) 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US20050287159A1 (en) * 2002-03-25 2005-12-29 Drivas Dimitrios T Treatment methods for eotaxin mediated inflammatory conditons
CN101052415A (zh) * 2003-03-24 2007-10-10 莫西亚药物公司 用于治疗和预防炎性疾病的方法和组合物
AR046594A1 (es) * 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
US9789171B2 (en) 2004-11-05 2017-10-17 The General Hospital Corporation Anti-fugetactic agents for the treatment of ovarian cancer
US20080268478A1 (en) * 2005-03-01 2008-10-30 Cedars-Sinai Medical Center Use of Eotaxin as a Diagnostic Indicator For Atherosclerosis and Vascular Inflammation
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US7304818B2 (en) * 2005-10-07 2007-12-04 Seagate Technology Llc Preconditioning an elastomeric stop member for use as a reference position
US20130053257A1 (en) * 2010-02-08 2013-02-28 Paul E. Oran RANTES Multiplexed Assay, RANTES Variants Related to Disease, and RANTES Variants Related to Enzymatice Activity
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
JPWO2018139404A1 (ja) * 2017-01-24 2019-11-14 協和キリン株式会社 放射線障害の治療又は予防剤並びに治療又は予防方法
US12221463B2 (en) 2020-08-07 2025-02-11 The Board Of Regents Of The University Of Oklahoma Method of promoting wound healing by inhibiting CCR3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3447978A (en) * 1967-08-03 1969-06-03 Atlas Chem Ind Ammonium nitrate emulsion blasting agent and method of preparing same
US5079228A (en) * 1990-02-05 1992-01-07 Board Of Regents, The University Of Texas System Peptide inhibitors of neutrophil activating factor induced chemotaxis
AU3078892A (en) * 1991-12-04 1993-06-28 Biomedical Research Centre Limited, The Human interleukin-8 analogs
RU94046275A (ru) * 1992-06-29 1996-09-27 Е.И.Дю Пон де Немурс энд Компани (US) Азеотропная композиция пентафторэтана и трифторэтана
US5514555A (en) * 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
JPH09507211A (ja) * 1993-09-14 1997-07-22 ナショナル ハート アンド ラング インスティチュート エオタキシン：好酸球走化性サイトカイン
US5385443A (en) 1993-10-12 1995-01-31 Les Traitements Des Eaux Poseidon Inc. Centrifugal liquid pump with internal gas injection assembly
WO1995031467A1 (en) * 1994-05-16 1995-11-23 Human Genome Sciences, Inc. Monocyte chemotactic protein-4
US6403782B1 (en) * 1995-06-22 2002-06-11 President And Fellows Of Harvard College Nucleic acid encoding eotaxin

Also Published As

Publication number Publication date
US20060178504A1 (en) 2006-08-10
US6605702B2 (en) 2003-08-12
NZ273052A (en) 1997-12-19
ES2274514T3 (es) 2007-05-16
US20020081623A1 (en) 2002-06-27
ES2274514T5 (es) 2014-06-09
AU687872B2 (en) 1998-03-05
ATE344324T1 (de) 2006-11-15
US5993814A (en) 1999-11-30
WO1995007985A1 (en) 1995-03-23
US20050176931A1 (en) 2005-08-11
CA2171761A1 (en) 1995-03-23
PT719331E (pt) 2007-01-31
EP0719331B2 (en) 2014-02-26
EP0719331B1 (en) 2006-11-02
US6031080A (en) 2000-02-29
EP0719331A1 (en) 1996-07-03
DK0719331T3 (da) 2006-12-04
DE69434878T3 (de) 2014-07-17
DE69434878D1 (en) 2006-12-14
CA2171761C (en) 2011-11-15
JPH09507211A (ja) 1997-07-22
US6635251B1 (en) 2003-10-21
AU7620594A (en) 1995-04-03
DE69434878T2 (de) 2007-03-01

Similar Documents

Publication Publication Date Title
DK0719331T3 (da) Eotaxin: Eosinophil chemotaktisk cytokin
IL115733A (en) Binding agents to cd23 and their use in the manufacture of a medicament
FI901489A0 (fi) Anordning foer i en roerformig ledning utfoerd fjaerrstyrd roerelse.
IT8805213A0 (it) Liberazione prolungata e controllata di peptidi insolubili in acqua
IT1229195B (it) Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
DK285388A (da) Peptid og dets anvendelse
DE3855800D1 (de) Magnetkopf und dessen Herstellungsverfahren
KR950703360A (ko) 미코박테리아 바케로부터의 치료제 및 hiv감염에 대한 그의 사용(therapeutic agent from mycobacterrium vaccae and its use against hiv infection)
DK0470972T3 (da) Kugleventil-aktiveringsorgan med kraftforstærker
ATE191923T1 (de) Interleukine-6 mutante mit verbesserter biologischer aktivität im vergleich zu wildtyp il-6
GEP20012489B (en) Use of Natural Human α-Interferon
ES2062398T3 (es) Aroil-ureas.
DK285288D0 (da) Peptid og dets anvendelse
EP0317860A3 (en) Preparation of monoolefinically unsaturated versatic-acid esters comprising one carboxylic group, and their use
IT8822934A0 (it) Composizioni farmaceutiche ad attivita' antidepressiva e ansiolitica
ITMI922579A0 (it) Derivato della (2-ammino-3,5-dibromo)-benzilammina ad azione antitussiva ed espettorante
ATE78173T1 (de) Human-wachstumshormon-derivat.
MY101875A (en) Lankacidin derivatives and production thereof.
ZA89585B (en) Human ifn-beta 2/il-6,its purification and use
IT1205171B (it) Dispositivo autofrenante per ruote piroettanti di sedie,poltrone e simili
IT8714727V0 (it) Accorgimenti per neutralizzare le ruotine ed altri mezzi valventi di trasperimento applicati a poltrone e mobili similari
IT8309569A0 (it) Applicazione terapeutica di farmaci ad attivita' antiproteolitica speci ficanel trattamento delle ulcere torpide
ITMI932362A0 (it) Derivato della (2-ammino-3,5-dibromo) benzilammina ad azione antitussiva ed espettorante
IT9019970A0 (it) Composizioni farmaceutiche ad attivita' riduttrice di radicali ossigeno e loro preparazione
ITMI913504A0 (it) Acidi 2,2-diacilaminoglutarici ad attivita' antiparkinsoniana e antipercinetica